Clinical Trials Browser

Ovarian Neoplasms × pegfilgrastim × Thoracic × Clear all

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Sarcoma, Triple Negative Breast Neoplasms

NCT02649673 2023-12-05

LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies

Phase 1 Terminated

34 enrolled

GynecologicThoracic

Lung Neoplasms, Ovarian Neoplasms, Small Cell Lung Carcinoma

NCT01059643 2019-09-18

A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck

Phase 2 Completed

103 enrolled 14 charts

GastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT00117442 2013-05-13

A Study of Carboplatin/Paclitaxel With Pegfilgrastim Supported by Haematopoietic Progenitor Cell Re-Infusion in Whole Blood

Phase 2 Completed

61 enrolled

BreastGynecologicThoracic

Breast Neoplasms, Lung Neoplasms, Ovarian Neoplasms

NCT00277160 2010-10-08

A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer

Phase 4 Completed

852 enrolled

BreastGynecologicLymphoidThoracic

Breast Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neutropenia, Ovarian Neoplasms

Clinical Trials

Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies

A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck

A Study of Carboplatin/Paclitaxel With Pegfilgrastim Supported by Haematopoietic Progenitor Cell Re-Infusion in Whole Blood

A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer